Clinical trials
Every registered trial of Ziconotide (Prialt)
14 studies, 4 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on Ziconotide (Prialt) has been registered.
- 14 registered studies in total.
- 4 are still enrolling people, so this is active research, not just history.
What kind of research
- 9 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 759 people took part in those.
- A further 5 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 6 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 3 have published results in the medical literature that anyone can read.
- The research spans 6 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 14 of 14 trials for Ziconotide (Prialt).
Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
Clinique Bizet
Pancreatic Cancer Pain · Intrathecal Analgesic · Intrathecal Administration of the Drug · Pancreatic Carcinoma
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy
Christian Hospital Northeast Northwest
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Ziconotide for Non-cancer Pain by Intrathecal Administration
ESTEVE Pharmaceuticals SAS
Pain, Chronic
OP2C : Prialt® Observatory in Clinical Practice
Institut Cancerologie de l'Ouest
Refractory Pain
Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic
Hospices Civils de Lyon
Severe Refractory Neuropathic Pain · Spinal Cord Lesions
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Ziconotide as First-Line IDT
Albany Medical College
Neuropathic Pain
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
Aaron Boster
Painful Myelopathy · Painful Neuropathy
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
Jazz Pharmaceuticals
Patients With Severe Chronic Pain
Intrathecal Bolus Doses of Ziconotide
University Hospital, Linkoeping
Peripheral Neuropathy
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
National Cancer Institute, Naples
Pain · Neuropathic Pain · Intractable Pain · Cancer
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Eisai Limited
Pain Management · Severe Chronic Pain
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain
Elan Pharmaceuticals
Pain
Prialt (Ziconotide) In Severe Chronic Pain
Elan Pharmaceuticals
Pain
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain
Neurex
HIV Infections · Cancer · Pain
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Ziconotide (Prialt) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.